Candida auris is a rapidly spreading virulent pathogen frequently resistant to multiple antifungal drugs that can form biofilms and infect wounds. Hence, there is a need for C. auris wound treatments not posing risks for developing antifungal resistance. We tested the ability of a polygalacturonic and caprylic acid ointment (PG+CAP) to rapidly eradicate C. auris biofilms within 2-hour exposures in an in vitro model. Medical-grade honey (MediHoney) wound ointment was used as a comparator. Nine different C. auris strains were tested. PG+CAP eradicated biofilms of 8 of the 9 tested strains and produced a > 5-log reduction of the ninth. MediHoney produced reductions ranging from 2 to 4 log without fully eradicating any strains. The differences between PG+CAP and MediHoney were statistically significant (p < 0.05). These results suggest that PG+CAP is a promising antimicrobial ointment warranting further in vivo study in wounds which may be colonized by C. auris biofilms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mycmed.2024.101519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in candida species isolated in africa.
Expert Rev Anti Infect Ther
January 2025
Pathogenic Yeast Research Group, Department of Microbiology and Biochemistry, University of the Free State, Bloemfontein, South Africa.
Introduction: There is a rise in antifungal resistance as well as the emergence of multidrug resistant fungal pathogens worldwide, including in Africa.
Method: This systematic review summarized the published data on the mechanisms and epidemiology of antifungal resistance in species in Africa between 2000 and early 2024.
Result: Seventeen reports from seven African countries were analyzed but due to the paucity of data, the prevalence of antifungal resistant isolates in Africa could not be estimated.
An overview of healthcare-associated Candida auris outbreaks in Ministry of Health hospitals-Saudi Arabia 2020-2022; Retrospective multicentric study.
PLoS One
January 2025
General Directorate of Infection Prevention & Control, Ministry of Health-Saudi Arabia, Riyadh, Saudi Arabia.
Background: Candida auris (C. auris) is an emerging fungus pathogen associated with nosocomial infections that is seen as a serious global health issue.
Aim: To describe the epidemiology and features of hospital-acquired Candida auris outbreaks in the Ministry of Health hospitals (MOH).
Genetic and Phenotypic Intra-Clade Variation in Candida auris Isolated from Critically Ill Patients in a New York City Tertiary Care Center.
Clin Chem
January 2025
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Background: Candida auris is an emerging multidrug-resistant pathogen. Interpretation of susceptibility testing can be difficult since minimum inhibitory concentration (MIC) breakpoints have not been fully established.
Methods: All C.
Minimal domain peptides derived from enterocins exhibit potent antifungal activity.
Front Fungal Biol
December 2024
Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, United States.
The antimicrobial peptide (AMP) circularized bacteriocin enterocin AS-48 produced by sp. exhibits broad-spectrum antibacterial activity via dimer insertion into the plasma membrane to form membrane pore structures, compromising membrane integrity and leading to bactericidal activity. A specific alpha-helical region of enterocin AS-48 has been shown to be responsible for the membrane-penetrating activity of the peptide.
View Article and Find Full Text PDFIsolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.
Mycopathologia
December 2024
Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Nagyerdei Krt. 98., Debrecen, 4032, Hungary.
The sudden emergence of multidrug- and pan-resistant Candida auris isolates, combined with limited treatment options, poses significant global challenges in healthcare settings. Combination based therapies are promising alternative options to overcome C. auris related infections, where echinocandin and isavuconazole (ISA) combinations may be an interesting and promising approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!